Oncotarget

Research Papers:

Methylated claudin-11 associated with metastasis and poor survival of colorectal cancer

Jinyun Li, Chongchang Zhou, Shumin Ni, Shaomin Wang, Chao Ni, Ping Yang and Meng Ye _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2017; 8:96249-96262. https://doi.org/10.18632/oncotarget.21997

Metrics: PDF 317 views  |   HTML 1389 views  |   ?  


Abstract

Jinyun Li1, Chongchang Zhou2, Shumin Ni1, Shaomin Wang1, Chao Ni3, Ping Yang3 and Meng Ye1

1Department of Oncology and Hematology, Affiliated Hospital, Medical School of Ningbo University, Ningbo, Zhejiang 315000, China

2Department of Otorhinolaryngology Head and Neck Surgery, Lihuili Hospital of Ningbo University, Ningbo 315040, Zhejiang, China

3Medical School, Ningbo University, Ningbo, Zhejiang 315211, China

Correspondence to:

Meng Ye, email: yemeng@nbu.edu.cn

Keywords: DNA methylation; colorectal cancer; claudin-11; metastasis; progression free survival

Received: June 06, 2017     Accepted: August 17, 2017     Published: October 23, 2017

ABSTRACT

As one of crucial epigenetic modification, DNA methylation plays an important role during the carcinogenesis of colorectal cancer (CRC). In the current study, we used a human genome methylation array to detect the aberrant methylation genes in CRC. We further identified the hypermethylation of claudin-11 (CLDN11) and proved inverse correlation between CLDN11 methylation and its expression in CRC. In vitro experiments showed debased migration ability of colonic cancer cells in accompany with the converted methylation of CLDN11 after colonic cancer cells treated with demethylation agent, 5-aza-2’-deoxycytidine. Besides, our results also represented that hypermethylation of CLDN11 was associated with increased metastatic potential of CRC and with low progression free survival (PFS) of CRC. In conclusion, our findings supported that the hypermethylated CLDN11 is associated with metastasis of CRC and prognosis of poor survival of CRC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21997